The company announced Bioma4me has implemented SOPHiA DDM to support its rare disorder testing capabilities
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine to the Brazilian population, is now live on the SOPHiA DDM Platform. The company will use SOPHiA GENETICS’ technology to advance and streamline its genetic testing capabilities.
Bioma4me is a leader in Brazil in providing personalized medicine, supported by genetic analysis of each individual, offered at an affordable cost, with great precision and in the shortest possible time.
Recommended AI News: CareCloud is Streamlining Healthcare with Smart Technology for All Practices
“We are thrilled to announce our collaboration with SOPHiA GENETICS, a leader in AI to further precision medicine. This partnership marks a significant milestone in the journey of scientific discovery and innovation for Bioma4me,” said Rafael Malagoli Rocha, PhD, Sócio Diretor, Bioma4me. “This collaboration is a fusion of expertise in order to drive forward the frontiers of human genetics and metagenomics in Latin America. Bioma4me is committed to unlocking new possibilities and advancing the field of oncology, microbiome, and genetic diseases in general, bringing hope and answers to our community. We celebrate this partnership as a testament to what can be achieved in the novelties in data-driven medicine.”
Recommended AI News: Samsung Introduces Lunit AI Solutions for Enhanced Chest Screenings
Through the SOPHiA DDM™ Platform, Bioma4me will be able to apply its next-generation sequencing (NGS) expertise to the whole exome. The SOPHiA DDM™ Platform will help the company streamline and expedite data analysis, which will save valuable time for clinical researchers and support the enablement of precision medicine for customers.
“We believe in advancing the use of precision medicine globally, supporting researchers and clinicians with our AI-based SOPHiA DDM™ Platform to help advance cancer research and provide better health outcomes worldwide,” said Ricardo Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS. “By using our platform, Bioma4me will be able to enhance and expedite its testing capabilities to deliver a comprehensive panel for its customers.”
The SOPHiA DDM™ Platform will enable Bioma4me fast turnaround time for results. Additionally, Bioma4me will have full ownership over its data and access to the SOPHiA GENETICS decentralized global network, helping to continuously advance its researchers’ capabilities and knowledge base.
Recommended AI News: Variational AI Announces Generative AI Project With Merck
[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]
Comments are closed.